Pharming Group (NASDAQ:PHAR) Shares Down 5%

Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) were down 5% during trading on Tuesday . The company traded as low as $10.11 and last traded at $10.12. Approximately 3,575 shares were traded during trading, an increase of 51% from the average daily volume of 2,372 shares. The stock had previously closed at $10.65.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 14th.

Pharming Group Trading Down 6.1 %

The stock has a market capitalization of $671.11 million, a price-to-earnings ratio of -71.42 and a beta of 0.16. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.33 and a current ratio of 4.06. The firm has a fifty day moving average of $11.32 and a 200-day moving average of $11.60.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The company had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. As a group, equities analysts predict that Pharming Group will post -0.02 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC bought a new stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 11,715 shares of the company's stock, valued at approximately $134,000. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.